Latest market price
81.11
+1.69+2.13%
TA
Loading chart...
Snapshot
| Index | — | P/E | 42.47 | EPS (ttm) | 1.87 | Insider Own | 20.68% | Shs Outstand | 12.79M | Perf Week | -6.16% |
| Market Cap | 1.02B | Forward P/E | 32.86 | EPS next Y | 2.42 | Insider Trans | -1.25% | Shs Float | 8.33M | Perf Month | -7.00% |
| Enterprise Value | 952.54M | PEG | 3.24 | EPS next Q | 0.61 | Short Float | 8.05% | Perf Quarter | -14.72% | ||
| Income | 24.00M | P/S | 11.41 | EPS this Y | 12.42% | Short Ratio | 5.46 | Perf Half Y | -6.48% | ||
| Sales | 89.00M | P/B | 9.58 | EPS next Y | 15.26% | ROA | 19.81% | Short Interest | 670.18K | Perf YTD | -18.36% |
| Book/sh | 8.29 | P/C | 16.12 | EPS next 5Y | 13.09% | ROE | 23.90% | 52W High | 107.90 -24.83% | Perf Year | 3.93% |
| Cash/sh | 4.93 | P/FCF | 39.06 | EPS past 3/5Y | 19.71% 73.91% | ROIC | 20.09% | 52W Low | 76.35 6.23% | Perf 3Y | 100.05% |
| Dividend Est. | 0.80 (0.99%) | EV/EBITDA | 29.77 | Sales past 3/5Y | 16.59% 21.29% | Gross Margin | 75.51% | Volatility | 3.13% 2.57% | Perf 5Y | 116.82% |
| Dividend TTM | 1.27 (1.57%) | EV/Sales | 10.70 | EPS Y/Y TTM | 13.33% | Oper. Margin | 32.30% | ATR (14) | 2.65 | Perf 10Y | 706.29% |
| Dividend Ex-Date | Aug 14, 2026 | Quick Ratio | 8.99 | Sales Y/Y TTM | 11.25% | Profit Margin | 26.85% | RSI (14) | 35.22 | Recom | 2.00 |
| Dividend Gr. 3/5Y | 5.67% — | Current Ratio | 8.99 | EPS Q/Q | 17.02% | SMA20 | -7.74% | Beta | 0.93 | Target Price | 100.00 |
| Payout | 67.65% | Debt/Eq | 0.00 | Sales Q/Q | 14.29% | SMA50 | -7.10% | Rel Volume | 1.69 | Prev Close | 79.42 |
| Employees | 166 | LT Debt/Eq | 0.00 | Earnings | Feb 09 | SMA200 | -14.07% | Avg Volume | 120.69K | Price | 81.11 |
| IPO Date | Jul 16, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.00% 3.13% | Net Debt/EBITDA | -1.97 | Volume | 203,471 | Change | 2.13% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-11-26 | Reiterated | Lake Street | $100 → $120 | |
| Feb-10-26 | Reiterated | Roth Capital | Buy | $98 → $120 |
| Nov-03-25 | Reiterated | Roth Capital | Buy | $90 → $98 |
| Nov-03-25 | Reiterated | Lake Street | $75 → $100 | |
| Oct-31-25 | Resumed | Roth Capital | Buy | $60 → $90 |
| Aug-02-24 | Reiterated | Roth Capital | Buy | $65 → $60 |
| Jun-17-24 | Reiterated | Loop Capital Markets | $60 | |
| Jul-31-17 | Upgrade | Roth Capital | Neutral → Buy | |
| Oct-05-16 | Downgrade | Roth Capital | Buy → Neutral |
Latest News· Times ET
Oct-30-26
01:38PM
IRADIMED CORPORATION (IRMD) Q3 2026 Earnings Call Transcriptseekingalpha.com
08:30AM
IRADIMED CORPORATION Reports Third Quarter 2026 Financial Resultsglobenewswire.com
Oct-28-26
Oct-26-26
Oct-23-26
Oct-23-2608:30AM
Sep-23-26
Sep-23-2609:00AM
Sep-22-26
Sep-16-26
Sep-16-2601:15AM
Sep-04-26
Sep-04-2608:00PM
Aug-27-26
Aug-10-26
Aug-10-2604:15AM
Aug-04-26
Jul-31-26
Company
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 89 | 84 | 73 | 66 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 22 | 19 | 17 | 15 | — | — | — | — | — | |
| Gross Profit | 67 | 64 | 56 | 50 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 35 | 35 | 32 | 27 | — | — | — | — | — | |
| Research and Development | 4 | 3 | 3 | 3 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -1 | 0 | — | — | — | — | — | |
| Operating Income | 28 | 26 | 22 | 20 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 3 | 2 | 2 | 2 | — | — | — | — | — | |
| Net Income Before Taxes | 32 | 28 | 24 | 22 | — | — | — | — | — | |
| Income Taxes | 7 | 6 | 5 | 5 | — | — | — | — | — | |
| Consolidated Net Income | 24 | 22 | 19 | 17 | — | — | — | — | — | |
| Net Income From Continuing Operations | 24 | 22 | 19 | 17 | — | — | — | — | — | |
| Net Income | 24 | 22 | 19 | 17 | — | — | — | — | — | |
| EPS (Recurring) | 1.89 | 1.77 | 1.52 | 1.36 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.89 | 1.77 | 1.52 | 1.36 | — | — | — | — | — | |
| EPS (Diluted) | 1.87 | 1.75 | 1.50 | 1.35 | — | — | — | — | — | |
| EBITDA | 32 | 30 | 25 | 23 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 43.37 | 55.59 | 36.67 | 35.16 | — | — | — | — | — | |
| Price To Sales Ratio | 11.85 | 15.06 | 9.79 | 9.35 | — | — | — | — | — | |
| Gross Margin | 75.28 | 76.19 | 76.71 | 75.76 | — | — | — | — | — | |
| Operating Margin | 31.46 | 30.95 | 30.14 | 30.30 | — | — | — | — | — | |
| Net Margin | 26.97 | 26.19 | 26.03 | 25.76 | — | — | — | — | — | |
| Shares Outstanding | 13 | 13 | 13 | 13 | — | — | — | — | — | |
| Market Capitalization | 1,054 | 1,265 | 715 | 617 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| KIANI JOE E | Director | Sep 23 '26 | Option Exercise | 0.00 | 698 | 0 | 698 | Sep 25 |
| ALLEN MONTY K | Director | Sep 03 '26 | Sale | 86.41 | 1,419 | 122,622 | 19,581 | Sep 08 |
| GLENN JOHN | CFO | Jun 20 '26 | Option Exercise | 0.00 | 5,796 | 0 | 14,256 | Jun 23 |
| Scharen-Guivel Hilda Frederique | Director | Jun 04 '26 | Sale | 95.00 | 3,000 | 285,000 | 5,598 | Jun 04 |
| Susi Roger E. | CEO, President, Chairman | Jun 01 '26 | Sale | 90.60 | 2,500 | 226,507 | 2,162,500 | Jun 02 |
| Susi Roger E. | CEO, President, Chairman | May 27 '26 | Sale | 91.95 | 2,500 | 229,878 | 2,165,000 | May 28 |
| Susi Roger E. | CEO, President, Chairman | May 26 '26 | Sale | 92.23 | 5,000 | 461,166 | 2,167,500 | May 28 |
| Susi Roger E. | CEO, President, Chairman | May 19 '26 | Sale | 87.88 | 2,500 | 219,694 | 2,172,500 | May 20 |
| Susi Roger E. | CEO, President, Chairman | May 18 '26 | Sale | 87.51 | 5,000 | 437,571 | 2,175,000 | May 20 |
| Susi Roger E. | CEO, President, Chairman | May 12 '26 | Sale | 83.92 | 4,411 | 370,183 | 2,180,000 | May 13 |
| Susi Roger E. | CEO, President, Chairman | May 11 '26 | Sale | 84.54 | 3,089 | 261,158 | 2,184,411 | May 13 |
| Susi Roger E. | CEO, President, Chairman | May 05 '26 | Sale | 85.74 | 3,750 | 321,529 | 2,187,500 | May 06 |
| Susi Roger E. | CEO, President, Chairman | May 04 '26 | Sale | 85.69 | 3,750 | 321,333 | 2,191,250 | May 06 |
| Susi Roger E. | CEO, President, Chairman | Apr 28 '26 | Sale | 86.23 | 3,750 | 323,364 | 2,195,000 | Apr 30 |
| Susi Roger E. | CEO, President, Chairman | Apr 27 '26 | Sale | 89.16 | 3,750 | 334,346 | 2,198,750 | Apr 30 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.